Directly acting antivirals against hepatitis C virus

Re-treatment of Patients With Chronic Hepatitis C Who Do Not Respond to Peginterferon-α2b

(2013) Donald M. Jensen   ANNALS OF INTERNAL MEDICINE

Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV–HCV-coinfected patients

(2011) Ana Treviño et al.   ANTIVIRAL THERAPY

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

(2011) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

A New Era of Hepatitis C Therapy Begins

(2011) Donald M. Jensen   NEW ENGLAND JOURNAL OF MEDICINE

Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

(2011) Bruce R. Bacon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Susceptibility of Treatment-Naive Hepatitis C Virus (HCV) Clinical Isolates to HCV Protease Inhibitors

(2010) A. Bae et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Modeling the Probability of Sustained Virological Response to Therapy with Pegylated Interferon plus Ribavirin in Patients Coinfected with Hepatitis C Virus and HIV

(2010) Jose Medrano et al.   CLINICAL INFECTIOUS DISEASES

Telaprevir Is Effective Given Every 8 or 12 Hours With Ribavirin and Peginterferon Alfa-2a or -2b to Patients With Chronic Hepatitis C

(2010) Patrick Marcellin et al.   GASTROENTEROLOGY

Recombinant HCV Variants With NS5A From Genotypes 1–7 Have Different Sensitivities to an NS5A Inhibitor but Not Interferon-α

(2010) Troels K.H. Scheel et al.   GASTROENTEROLOGY

Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C

(2010) Fred Poordad et al.   HEPATOLOGY

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection

(2010) Andrew J. Muir et al.   HEPATOLOGY

Corrigendum to “Acute hepatitis caused by a natural lipid-lowering product: When “alternative” medicine is no “alternative” at all” [J Hepatol 50 (2009) 1273–1277]

(2010) Antonio Grieco et al.   JOURNAL OF HEPATOLOGY

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection

(2010) Michael P. Manns et al.   JOURNAL OF HEPATOLOGY

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

(2010) Paul Y Kwo et al.   LANCET

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

(2010) Edward J Gane et al.   LANCET

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

(2010) Min Gao et al.   NATURE

DEB025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A

(2010) Lotte Coelmont et al.   PLoS One

GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796

(2009) M. F. McCown et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

New Therapies for Hepatitis C Virus Infection

(2009) Vincent Soriano et al.   CLINICAL INFECTIOUS DISEASES

Rapid HCV-RNA Decline With Once Daily TMC435: A Phase I Study in Healthy Volunteers and Hepatitis C Patients

(2009) Henk W. Reesink et al.   GASTROENTEROLOGY

Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection

(2009) Christoph Sarrazin et al.   GASTROENTEROLOGY

A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results

(2009) Yves Benhamou et al.   HEPATOLOGY

Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs)

(2009) T. L. Kieffer et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Evaluation of VCH-759 monotherapy in hepatitis C infection

(2009) Curtis Cooper et al.   JOURNAL OF HEPATOLOGY

The role of new interferons in the era of STAT-C

(2009) Rami Moucari et al.   Nature Reviews Gastroenterology & Hepatology

Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV Infection

(2009) Christophe Hézode et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection

(2009) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479

(2008) S. Ali et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

(2008) M. F. McCown et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Tailored Treatment for Hepatitis C

(2008) Thomas Berg   Clinics in Liver Disease

The emerging field of HCV drug resistance

(2008) Gennadiy Koev et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy

(2008) Silvana Gaudieri et al.   HEPATOLOGY

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

(2008) Thomas Kuntzen et al.   HEPATOLOGY

Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?

(2008) V. Soriano et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Natural Prevalence of Hepatitis C Virus Variants with Decreased Sensitivity to NS3·4A Protease Inhibitors in Treatment‐Naive Subjects

(2008) Doug J. Bartels et al.   JOURNAL OF INFECTIOUS DISEASES

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

(2008) Adrian M. Di Bisceglie et al.   NEW ENGLAND JOURNAL OF MEDICINE